Intelligent Bio Solutions Inc. provided unaudited preliminary earnings guidance for the second quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.305 USD | -4.36% | +2.44% | -43.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.15% | 6.57M | |
-32.63% | 9.2B | |
-5.66% | 3.12B | |
-18.33% | 2.05B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.77% | 720M | |
-29.80% | 507M | |
+0.40% | 297M |
- Stock Market
- Equities
- INBS Stock
- News Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023